Catch up on the top radiology content of the past week.
News|Slideshows|September 27, 2026
Radiology Roundup of FDA News: September 20 — September 26
Author(s)Diagnostic Imaging Staff
Catch up on a variety of FDA news in radiology from the past week.
Advertisement
From emerging AI triage software platforms for chest X-ray and abdominopelvic CT to a final FDA approval of the radiopharmaceutivcal Bravnetsa for treating somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), here are key FDA news developments in radiology from the past week.
Advertisement
Related to this article
Catch up on the top AI-related news and research in radiology over the past month.
In the first of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss current challenges with reimbursement for AI in radiology.
Catch up on the top radiology content of the past week.
In a recent interview, Shadpour Demehri, MD, discussed new research examining connections between deep learning assessment of bone mineral density on chest CT, brain MRI data and the potential for enhanced risk stratification in patients with diabetes.
In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
Catch up on a variety of FDA news in radiology from the past week.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging's Weekly Scan: September 20 — September 26
2
Study Links AI BMD Assessment on Chest CT to Faster Cognitive Decline and White Matter Changes on Brain MRI
3
Radiology Roundup of FDA News: September 20 — September 26
4
Advances in AI — September 2026
5